Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways

Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways

Abstract This study aimed to investigate the role and signaling pathways of β3-AR in myocardial ischemia/reperfusion (I/R) injury, which is one of the leading causes of death worldwide. 47 male rats were randomly divided into two main groups to evaluate infarct size and molecular parameters. Rats in...

Full description

Bibliographic Details
Main Authors: Dilan Askin Ozek, Elif Onat, Kazim Sahin, Mehmet Tuzcu, Merve Yilmaz Bozoglan, Engin Sahna
Format: Article
Language:English
Published: Universidade de São Paulo 2023-11-01
Series:Brazilian Journal of Pharmaceutical Sciences
Subjects:
Adenosine monophosphate-activated protein kinase (AMPK)
Beta3-adrenergic receptors
Myocardial Ischemia/Reperfusion
Mammalian target of rapamycin (mTOR)
Sirtuin 1 (SIRT1).
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502023000100421&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502023000100421&tlng=en

Similar Items